Recombinant bovine somatotropin and clinical mastitis: incidence, discarded milk following therapy, and culling.
Holstein cows (n = 555) from four Michigan dairy farms were randomly assigned to receive bovine somatotropin (bST) or to serve as untreated controls. Bovine somatotropin (500 mg) was administered every 14 d beginning at 63 to 69 d of lactation and continuing until approximately 21 d prior to dry-off or until the cow was removed from the herd. Trial objectives were to determine the effect of bST on the incidence of clinical mastitis, number of days that milk was discarded because of therapy for clinical mastitis, and culling for mastitis. A total of 127 (22.9%) cases of clinical mastitis occurred during lactation. In the pretrial period (before 63 to 69 d of lactation), 42 (33.1%) cases occurred, and 85 (66.9%) cases occurred during the trial. Of the 42 pretrial cases, 57.1% occurred in control cows, and 42.9% occurred in treated cows. Of the 85 trial cases 47.1% occurred in control cows, and 52.9% occurred in treated cows. Using logistic regression, the odds ratio for the occurrence of clinical mastitis in treated cows was 1.06 (95% confidence interval = 0.62 to 1.81). The number of days that milk was discarded following therapy for clinical mastitis and the culling rate for mastitis did not differ between study groups.
Judge
L J
LJ
Department of Large Animal Clinical Sciences, Michigan State University, East Lansing 48824, USA.
Erskine
R J
RJ
Bartlett
P C
PC
D000818:Animals; D002417:Cattle; D005260:Female; D006090:Gram-Negative Bacteria / Q000302:isolation & purification; D013006:Growth Hormone / Q000494:pharmacology*; D007774:Lactation; D016015:Logistic Models; D008414:Mastitis, Bovine / Q000188:drug therapy* / Q000453:epidemiology*; D008892:Milk / Q000382:microbiology*; D013291:Streptococcus / Q000302:isolation & purification
D013006:Growth Hormone